Skip to main
DMRA

Galecto Inc (DMRA) Stock Forecast & Price Target

Galecto Inc (DMRA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Damora Therapeutics is a biotechnology company with a promising drug pipeline focused on addressing crucial medical needs in the treatment of hematologic disorders. Their drugs target a specific mutation with potential for monthly dosing, and the company has a first-mover advantage in this market. While risks in the development timeline should be considered, the company's financial status and potential for improved patient outcomes make it an attractive investment opportunity.

Bears say

Damora Therapeutics is currently facing stiff competition in the market for treatments for mutCALR-driven myeloproliferative neoplasms, with other companies also working on potential solutions. While their lead product, DMR-001, has shown promising results in early trials, potential regulatory challenges and market challenges may impact its success. Additionally, the company's success will depend on their ability to effectively develop and commercialize their pipeline products and their ability to differentiate themselves from other players in the market.

Galecto Inc (DMRA) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Galecto Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Galecto Inc (DMRA) Forecast

Analysts have given Galecto Inc (DMRA) a Buy based on their latest research and market trends.

According to 4 analysts, Galecto Inc (DMRA) has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Galecto Inc (DMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.